Pediatric Study Waiver, Deferral Determinations Could Harm Approvals, Firms Tell FDA
Executive Summary
Comments on draft guidance say agency’s belated decisions on requests for waivers or deferrals of pediatric studies could lead to “refuse to file” determinations; FDA has missed statutory deadline to promulgate regulations on pediatric study plans.
You may also be interested in...
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Study and formulation requirements under PREA mean that interchangeability application might not be much more of a leap.
Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say
FDA posts non-compliance letters and responses from three sponsors that failed to meet deadlines for submitting reports for trials of four drugs in children; more than 70 firms have had their deadlines extended.